Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man
- 137 Downloads
The pharmacokinetics of Δ9-tetrahydrocannabinol (THC) administered intravenously was evaluated in four subjects after oral administration of placebo and 1500 mg of cannabidiol (CBD) according to a crossover design. The cannabidiol pretreatment had no apparent effect on THC pharmacokinetics, yet there may have been minimal effect on the formation and excretion of metabolites. The total (metabolic) blood clearance of THC averaged 17.4 ml/min/kg without CBD and 20.9 ml/min/kg with CBD, and was probably hepatic blood flow limited. The apparent steady-state volume of distribution averaged 9.86 (with CBD, 10.54) liters/kg. Irrespective of CBD pretreatment, the renal clearance of THC metabolites ranged from 17 ml/min after approximately 1 hr to 1.13 ml/min 3.5days after dosing with THC. The apparent terminal half life for metabolites averaged 8.2 days.
Key wordscannabidiol tetrahydrocannabinol pharmacokinetics cannabinoids pharmacodynamics metabolism renal clearance protein binding
Unable to display preview. Download preview PDF.
- 6.A. J. Siemans, H. Kalant, and J. C. deNie. Metabolic interactions between delta-9-tetrahydrocannabinol and other cannabinoids in rats. In M. C. Braude and S. Szara (eds.),The Pharmacology of Marihuana, Raven Press, New York, 1976, pp. 77–92.Google Scholar
- 11.W. S. Dalton, R. Martz, B. E. Rodda, L. Lemberger, and R. B. Forney. Influence of cannabidiol on secobarbital effects and plasma kinetics.Clin. Pharmacol. Ther. 30:695–700 (1976).Google Scholar
- 15.C. A. Hunt and R. T. Jones. Tolerance and disposition of tetrahydrocannabinoi in man.J. Pharmacol. Exp. Ther. 215:35–44 (1981).Google Scholar
- 22.C. M. Metzler.A User's Manual for NONLIN, The Upjohn Co., Technical Report 7292/69/7292/005, 1969, Kalamazoo, Mich.Google Scholar
- 23.D. S. Riggs.The Mathematical Approach to Physiological Problems, 2nd edn. M.I.T. Press, Cambridge, Mass., 1972, pp. 146–161.Google Scholar